Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and twelve months ended December 31, 2025. The Company also filed its Annual Report on Form 10-K for the year ended December 31, 2025, with the Securities and Exchange Commission on March 10, 2026. Fourth Quarter 2025 OverviewRevenue increased 79.1% to $14.5 million from $8.1 million in the fourth quarter of 2024. Gross margin of 43.9% compared to 48.9% in the fourth quarter of 2024. Gross profit rose 60.7% to $6.4 million...

Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.         Three Months Ended December 31,   Year Ended December 31,  2025   2025(in thousands, except ASP data)  Revenue $ 16,631     $ 66,575  Gross margin   55.4 %     58.3 %Operating expenses $ 14,181     $ 52,869  Loss from operations $ (4,975 )   $ (14,070 )Net loss $ (4,673 )   $ (19,951 )Adjusted EBITDA $ (3,670 )   $ (9,794 )Cash, cash equivalents and restricted cash $32,420Trailing-twelve-month...

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients  Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs); regulatory update expected in 1H 2026 Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026 Completed oversubscribed $86 million public offering with participation from new and existing investors Cash, cash equivalents and investments of approximately...

Fourth Quarter Total Sales Up 19.5% Driven by Elevated Tooling Revenue; Full Year Business Wins of $63 Million Support Multi-Year Revenue Expansion COLUMBUS, Ohio, March 10, 2026 (GLOBE NEWSWIRE) — Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today reported financial and operating results for the fiscal periods ended December 31, 2025. David Duvall, the Company’s President and Chief Executive Officer, said, “Fiscal 2025 was intensely focused on our Invest For Growth Must Win Battle – and we delivered as stated. We won $63 million in business,...

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company HighlightsThe IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favorable emerging tolerability profile consistent with previous IMG-007 patient experience. The Company has submitted a protocol amendment intended to expand the number and exposure range of dosing regimens being evaluated, characterize the role of loading doses, evaluate patient-friendly dosing intervals, and understand the effect of short-...

Accident Year 2025 Underwriting Profitability Improves Across Every Quarter; Current Accident Year Combined Ratio Excluding California Wildfires Reaches 92.2% WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) — Global Indemnity Group, LLC (Nasdaq: GBLI) (the “Company”) today reported financial results for the twelve months ended December 31, 2025. The year was defined by two distinct narratives: a significant California Wildfire loss event in January 2025, and a steady, quarter-by-quarter improvement in underlying underwriting performance that continued through year end. Net losses from the California Wildfires totaled $15.7 million pre-tax ($12.0 million after-tax). Excluding this event, the Company’s current accident year combined ratio improved in each successive period throughout 2025, reaching 92.2% for the...

MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights:Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially. 208% increase in U.S. console sales in Q4 versus prior year quarter. Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4. Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter. Closed a $5.0 million private placement and warrant inducement transaction in January 2026, strengthening the Company’s capital position. Appointed Carisa Schultz as Chief...

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for PRT13722 in mid-2026 with Phase 1 study initiation anticipated in the 2nd half of 2026 Current cash runway expected into second quarter of 2027 with $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025  WILMINGTON, Del., March 10, 2026 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its...

Delivers Record Pre-Tax Income of $160.6 Million and Record Revenue of $730.2 Million COCONUT CREEK, Fla., March 10, 2026 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced its financial results for the year ended December 31, 2025. 2025 Highlights (All metrics compared to 2024, except if noted)Record high annual total revenue of $730.2 million, an increase of 28.3% Record high pre-tax income of $160.6 million, an increase of 5.2% Record high lease rent revenue of $291.6 million, an increase of 22.4% Record high maintenance reserve revenue of $232.0 million, an increase of 8.4% Record high spare parts and equipment sales of $95.5 million, an increase of 252.3% Record high gain...

Revenue was $2.2 billion, an increase of 6.1% over the prior year, including organic growth of 5.5% Net income totaled $38.8 million, or $0.64 per diluted share, as compared to $43.6 million or $0.69 in the prior year Adjusted net income was $50.4 million, or $0.83 per diluted share, versus $55.3 million, or $0.87, in the prior year Adjusted EBITDA was $117.8 million, versus $120.6 million last year Operating cash flow was $62.0 million and free cash flow totaled $48.9 million, both up significantly over the prior year The Company repurchased $91.1 million of common stock during the quarter at an average price of $44.13 per shareNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) — ABM (NYSE: ABM), a leading provider of facility, engineering and infrastructure solutions, today announced financial results for its fiscal first quarter...